Drug Type Bispecific antibody |
Synonyms LM 24C5 |
Target |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), CEACAM5 modulators(Carcinoembryonic antigen related cell adhesion molecule 5 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 20 Dec 2023 | |
Colorectal Cancer | Phase 1 | CN | - | |
Gastrointestinal Neoplasms | Phase 1 | CN | - | |
Lung Cancer | Phase 1 | CN | - |